bluebird bio (BLUE)
(Real Time Quote from BATS)
$1.10 USD
+0.02 (1.85%)
Updated Aug 2, 2024 02:46 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Bluebird Bio (BLUE) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$3.78 | $8.00 | $1.00 | 250.00% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for Bluebird Bio comes to $3.78. The forecasts range from a low of $1.00 to a high of $8.00. The average price target represents an increase of 250% from the last closing price of $1.08.
Analyst Price Targets (9 )
Broker Rating
Bluebird Bio currently has an average brokerage recommendation (ABR) of 2.58 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 12 brokerage firms. The current ABR compares to an ABR of 2.62 a month ago based on 13 recommendations.
Of the 12 recommendations deriving the current ABR, four are Strong Buy, representing 33.33% of all recommendations. A month ago, Strong Buy represented 30.77%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 |
Buy | 0 | 0 | 0 | 0 | 1 |
Hold | 6 | 6 | 7 | 7 | 7 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 2.58 | 2.58 | 2.62 | 2.62 | 2.57 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/2/2024 | SVB Securities | Mani Foroohar | Hold | Hold |
6/30/2024 | Goldman Sachs | Salveen Richter | Strong Sell | Strong Sell |
5/9/2024 | William Blair | Sami Corwin | Hold | Hold |
3/27/2024 | Wells Fargo Securities | Yanan Zhu | Hold | Hold |
3/27/2024 | Not Identified | Not Identified | Hold | Hold |
3/15/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/8/2024 | Cantor Fitzgerald & Co | Eric Schmidt | Hold | Hold |
3/5/2024 | Not Identified | Not Identified | Moderate Sell | Moderate Sell |
12/12/2023 | Robert W. Baird & Co. | Jack K Allen | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.58 |
ABR (Last week) | 2.58 |
# of Recs in ABR | 12 |
Average Target Price | $3.78 |
LT Growth Rate | 26.00% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 88 of 253 |
Current Quarter EPS Est: | -0.43 |